High prevalence of confirmed, but also of potential and believed, neuropathic pain in pain clinics
Article first published online: 24 AUG 2012
© 2012 European Federation of International Association for the Study of Pain Chapters
European Journal of Pain
Volume 17, Issue 3, pages 347–356, March 2013
How to Cite
Pérez, C., Ribera, M.V., Gálvez, R., Micó, J.A., Barutell, C., Failde, I., Sánchez-Magro, I. and Stern, A. (2013), High prevalence of confirmed, but also of potential and believed, neuropathic pain in pain clinics. European Journal of Pain, 17: 347–356. doi: 10.1002/j.1532-2149.2012.00204.x
This research has been funded by Grünenthal Pharma, S.A.
Conflicts of interest
C.P., M.V.R., R.G., J.A.M., C.B and I.F. have not conflicts of interest to declare. I.S.-M and A.S. are full-time employees of Grünenthal Pharma, S.A.
- Issue published online: 6 FEB 2013
- Article first published online: 24 AUG 2012
- Manuscript Accepted: 16 JUL 2012
- Grünenthal Pharma, S.A.
Figure S1. Raw odds ratios of definite versus non-definite (possible or probable) neuropathic pain of patients with each diagnostic label compared with the remaining sample.
Table S1. Bivariate comparison of patients’ characteristics across levels of certainty of neuropathic pain diagnosis.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.